Hybio Pharmaceutical (300199) — Strategic Asset Allocation Index
Hybio Pharmaceutical (300199) has a Strategic Asset Allocation Index of 144.9% as of June 2023. Strategic assets (PP&E of CN¥1.86 Billion plus long-term investments of CN¥-) total CN¥1.86 Billion, measured against net assets of CN¥1.29 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Hybio Pharmaceutical Strategic Asset Allocation Index (2008–2022)
This chart shows how Hybio Pharmaceutical's Strategic Asset Allocation Index has evolved across 15 annual periods from 2008 to 2022. As of June 2023, the index stands at 144.9%, representing strategic assets of CN¥1.86 Billion against net assets of CN¥1.29 Billion CNY. Explore cash flow conversion of Hybio Pharmaceutical to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Hybio Pharmaceutical (2008–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Hybio Pharmaceutical from 2008 to 2022, covering 15 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see 300199 market cap.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 149.7% | CN¥1.94 Billion | CN¥1.94 Billion | CN¥- | CN¥1.30 Billion | ▲ +28.8 pp |
| 2021 | 120.9% | CN¥1.99 Billion | CN¥1.99 Billion | CN¥- | CN¥1.65 Billion | ▲ +2.9 pp |
| 2020 | 118.0% | CN¥1.98 Billion | CN¥1.98 Billion | CN¥- | CN¥1.68 Billion | ▲ +37.8 pp |
| 2019 | 80.2% | CN¥1.79 Billion | CN¥1.79 Billion | CN¥- | CN¥2.23 Billion | ▲ +34.6 pp |
| 2018 | 45.6% | CN¥1.55 Billion | CN¥1.33 Billion | CN¥217.71 Million | CN¥3.39 Billion | ▲ +14.4 pp |
| 2017 | 31.1% | CN¥1.21 Billion | CN¥1.06 Billion | CN¥149.95 Million | CN¥3.88 Billion | ▲ +0.1 pp |
| 2016 | 31.1% | CN¥1.12 Billion | CN¥965.08 Million | CN¥155.54 Million | CN¥3.60 Billion | ▼ -8.8 pp |
| 2015 | 39.9% | CN¥1.05 Billion | CN¥917.62 Million | CN¥134.29 Million | CN¥2.64 Billion | ▼ -1.6 pp |
| 2014 | 41.5% | CN¥537.70 Million | CN¥537.70 Million | CN¥- | CN¥1.30 Billion | ▼ -4.2 pp |
| 2013 | 45.7% | CN¥514.03 Million | CN¥514.03 Million | CN¥- | CN¥1.12 Billion | ▲ +16.6 pp |
| 2012 | 29.1% | CN¥295.85 Million | CN¥295.85 Million | CN¥- | CN¥1.02 Billion | ▲ +19.8 pp |
| 2011 | 9.3% | CN¥90.71 Million | CN¥90.71 Million | CN¥- | CN¥976.09 Million | ▼ -27.8 pp |
| 2010 | 37.1% | CN¥66.91 Million | CN¥66.91 Million | CN¥- | CN¥180.59 Million | ▼ -2.3 pp |
| 2009 | 39.3% | CN¥50.25 Million | CN¥50.25 Million | CN¥- | CN¥127.74 Million | ▼ -12.0 pp |
| 2008 | 51.3% | CN¥50.95 Million | CN¥50.95 Million | CN¥- | CN¥99.23 Million | — |